Granules India Limited (BOM:532482)
842.55
+8.90 (1.07%)
At close: Jul 27, 2026
Granules India Revenue
Granules India had revenue of 14.77B INR in the quarter ending June 30, 2026, with 22.04% growth. This brings the company's revenue in the last twelve months to 56.32B, up 24.83% year-over-year. In the fiscal year ending March 31, 2026, Granules India had annual revenue of 53.66B with 19.73% growth.
Revenue (ttm)
56.32B
Revenue Growth
+24.83%
P/S Ratio
3.71
Revenue / Employee
13.08M
Employees
4,306
Market Cap
208.78B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 53.66B | 8.84B | 19.73% |
| Mar 31, 2025 | 44.82B | -247.59M | -0.55% |
| Mar 31, 2024 | 45.06B | -55.50M | -0.12% |
| Mar 31, 2023 | 45.12B | 7.47B | 19.84% |
| Mar 31, 2022 | 37.65B | 5.27B | 16.29% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 82.80B |
| Abbott India | 69.29B |
| J. B. Chemicals & Pharmaceuticals | 41.48B |
| GlaxoSmithKline Pharmaceuticals | 38.22B |
| Viyash Scientific | 34.20B |
| AstraZeneca Pharma India | 22.76B |
| Caplin Point Laboratories | 21.87B |
| Sanofi India | 17.74B |
Granules India News
- 6 days ago - Granules India Transcript: Q1 26/27 - Transcripts
- 6 days ago - Granules India Quarterly report: Q1 2027 - Filings
- 6 days ago - Granules India Slides: Q1 2027 - Filings
- 6 days ago - Granules India's first-quarter profit surges as margins improve - Reuters
- 21 days ago - Granules India secures sole First-to-File status for generic drug - The Times of India
- 22 days ago - Granules India shares gain 2% after company secures Sole First-to-File status for Sodium Oxybate ANDA in US - Business Upturn
- 22 days ago - Granules India secures sole first-to-file ANDA status for sodium oxybate - Business Upturn
- 7 weeks ago - Granules India subsidiary receives USFDA EIR for Chantilly facility - Business Upturn